Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Síndromes Prader-Willi y Angelman: serie de casos diagnosticados mediante la técnica de MS-MLPA / Prader-Willi and Angelman syndromes: case series diagnosed by MS-MLPA assay
Resumen
Resumen
Introducción: el síndrome Prader-Willi (SPW) y el síndrome de Angelman (SA) son trastornos del neurodesarrollo producidos por deleciones o defectos de metilación que producen pérdida de expresión en los genes improntados de la región 15q11‑q13, mismos que pueden ser evaluados por diferentes técnicas citogenómicas y moleculares. Presentamos una serie de pacientes con SPW y SA en los que se identificó el tipo de defecto de la región 15q11-q13 mediante la técnica de MS-MLPA.
Casos clínicos: estudiamos cuatro pacientes con diagnóstico clínico de SPW y uno con SA, evaluados en lo posible con cariotipo, FISH y todos con ensayo MS-MLPA para la región 15q11-q13. En los pacientes con SPW, la hipotonía neonatal fue el motivo principal de consulta. En tres de ellos se identificó deleción de 15q11-q13 por MS-MLPA, confirmada por FISH, y en uno el patrón de metilación anormal fue compatible con una disomía uniparental materna. El paciente con SA presentó un cuadró típico y también se identificó una deleción en 15q11-q13 por MS-MLPA, confirmada por FISH.
Conclusiones: confirmamos que el uso de la técnica de MS-MLPA para la región 15q11‑q13 mostró ser de gran utilidad para identificar los mecanismos genómicos y epigenéticos implicados en el SPW y el SA.
Abstract
Background: Prader Willi syndrome (PWS) and Angelman syndrome (AS) are neurodevelopmental disorders caused by deletions or methylation defects, making a loss of expression of imprinted genes located in the 15q11-q13 region, and these can be assessed by different cytogenomic and molecular techniques. We report a case series of patients with PWS and AS evaluated through the MS-MLPA assay.
Clinical cases: We studied four patients with a clinical diagnosis of PWS and another with AS, evaluated as far as possible with karyotype and FISH, and with MS-MLPA assay for the 15q11-q13 region in all cases. In patients with PWS, neonatal hypotonia was the main reason for consultation and in three of them we identified a deletion of 15q11-q13 by MS-MLPA, also confirmed by FISH; and in the other one, an abnormal methylation pattern consistent with a maternal uniparental disomy. The patient with AS presented with a typical picture which led to the identification of a deletion in 15q11-q13 by MS-MLPA, also confirmed by FISH.
Conclusions: The use of the MS-MLPA assay for the 15q11-q13 region was very useful for the diagnosis and identification of the genomic and epigenetic defects involved in either PWS and AS.
Palabras clave
Referencias
Nicholls RD, Knoll JH, Butler MG, Karam S, Lalande M. Genetic imprinting suggested by maternal heterodisomy in nondeletion Prader-Willi syndrome. Nature. 1989;342(6247):281-5.
Butler MG, Miller JL, Forster JL. Prader-Willi syndrome - clinical genetics, diagnosis and treatment approaches: An update. Curr Pediatr Rev. 2019;15(4):207-44.
Butler MG, Kimonis V, Dykens E, Gold JA, Miller J, Tamura R, et al. Prader-Willi syndrome and early-onset morbid obesity NIH rare disease consortium: A review of natural history study. Am J Med Genet A. 2018;176(2):368-75.
Bonello D, Camilleri F, Calleja-Agius J. Angelman syndrome: Identification and management. Neonatal Network. 2017;36(3):142-51.
Dagli AI, Mueller J, Williams CA. Angelman syndrome. [Initial Posting: September 15, 1998; Last Revision: December 21, 2017]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (Eds). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.
Clayton-Smith J, Laan L. Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet. 2003;40(2):87-95.
Buiting K, Gross S, Lich C, Gillessen-Kaesbach G, el-Maarri O, Horsthemke B. Epimutations in Prader-Willi and Angelman syndromes: a molecular study of 136 patients with an imprinting defect. Am J Hum Genet. 2003;72(3):571-7.
Driscoll DJ, Miller JL, Schwartz S, Cassidy SB. Prader-Willi Syndrome. [Initial Posting: October 6, 1998; Last Revision: December 14, 2017]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (Eds). GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2020.
Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57.
Carrasco-Salas P, Martín-Mérida I. MLPA en el diagnóstico de enfermedades hereditarias. Ed Cont Lab Clin. 2018;37: 26‑32.
Vilchis Z, Najera N, Pérez-Duran J, Najera Z, Gonzalez L, del Refugio Rivera M, et al. The high frequency of genetic diseases in hypotonic infants referred by neuropediatrics. Am J Med Genet A. 2014;164A(7):1702-5.
Nájera N, González L, Pérez Durand J, Ruíz E, Garibay N, Pastrana Y, et al. Small nuclear ribonucleoprotein polypeptide N quantitative methylation analysis in infants with central hypotonia. J Pediatr Endocrinol Metab. 2011;24(7-8):595‑8.
Gunay-Aygun M, Schwartz S, Heeger S, O'Riordan MA, Cassidy SB. The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria. Pediatrics. 2001;108(5):E92.
Williams CA, Beaudet AL, Clayton-Smith J, Knoll JH, Kyllerman M, Laan LA, et al. Conference report Angelman syndrome 2005: Updated consensus for diagnostic criteria. Am J Med Genet. 2006;140A(5):413-8.
Bohonowych J, Miller J, McCandless SE, Strong TV. The Global Prader-Willi Syndrome Registry: Development, launch, and early demographics. Genes (Basel). 2019;10(9):713.
Beygo J, Buiting K, Ramsden SC, Ellis R, Clayton-Smith J, Kanber D. Update of the EMQN/ACGS best practice guidelines for molecular analysis of Prader-Willi and Angelman syndromes. Eur J Hum Genet. 2019;27(9):1326-40.
Procter M, Chou LS, Tang W, Jama M, Mao R. Molecular diagnosis of Prader-Willi and Angelman syndromes by methylation-specific melting analysis and methylation-specific multiplex ligation-dependent probe amplification. Clin Chem. 2006;52(7):1276-83.
Laurito SR, Roque Moreno M. Análisis de variación del número de copias y de patrones de metilación en la región 15q11-q13. Medicina (B Aires). 2018;78(1):1‑5.
Torrado M, Araoz V, Baialardo E, Abraldes K, Mazza C, Krochik G, et al. Clinical-etiologic correlation in children with Prader-Willi syndrome (PWS): an interdisciplinary study. Am J Med Genet A. 2007;143A(5):460-8.
Elena G, Bruna C, Benedetta M, Stefania DC, Giuseppe C. Prader-Willi syndrome: clinical aspects. J Obes. 2012;2012:473941.
Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med. 2017;19(6):635-42.
Cassidy S, Schwartz S, Miller J, Driscoll DJ. Prader-Willi syndrome. Genet Med. 2012;14(1):10-26.
Butler MG, Bittel DC, Kibiryeva N, Talebizadeh Z, Thompson T. Behavioral differences among subjects with Prader-Willi syndrome and type I or type II deletion and maternal disomy. Pediatrics. 2004;113(3 Pt 1):565-73.
Enlaces refback
- No hay ningún enlace refback.